India’s Pharma Industry Faces Unprecedented Challenges
India’s pharmaceutical industry has grown at record levels in recent years…
Continue reading
India’s Pharma Industry Faces Unprecedented Challenges
India’s pharmaceutical industry has grown at record levels in recent years…
Continue reading
As a pharmaceutical consultant, PDG understands that today’s drug manufacturers rely upon reformulation to prolong product lifecycles, protect…
Continue reading
Rx-to-OTC switches and the related repositioning of pharmaceutical products from prescription (Rx) dispensing to the retail (over-the-counter or…
Continue reading
Many have speculated that the era of the blockbuster drug has…
Continue reading
FDA recently announced that Fixed-Combination Drugs (FCD) comprised of at least one NCE will be eligible for 5…
Continue reading
In a move that was not entirely unexpected, FDA delayed publication of a rule proposed last year that…
Continue reading
PDG™ is a pharmaceutical consultant serving drug sponsors around the world. On July 28, 2014, PDG™ published a…
Continue reading
FDA recently granted a therapeutic equivalence (TE) rating of AB to a “generic” version of an innovator product…
Continue reading
As pharmaceutical consultants, PDG devotes considerable resources to both brand & generic drug safety surveillance and labeling issues.…
Continue reading
PDG provides pharmaceutical strategy and development consulting expertise and serves as our clients’ regulatory voice at FDA. Whether you require a 505(b)(1) or 505(b)(2) NDA, PDG employs pharmaceutical industry professionals who routinely and successfully present client-proposed regulatory strategies to the Agency.
Continue reading